Skip to main content
Year archive

Active Biotech — 2022 filings

All 42 regulatory filings released by Active Biotech (ACTI) in 2022, sourced directly from the official regulator.

42 Filings
2022 Period
2022 filings (42)
Filing Released Lang
Active Biotechs valberedning utsedd
Governance Information
2022-12-05 Swedish
Active Biotech's nomination committee appointed
Board/Management Information
2022-12-05 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-08 English
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-03 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q3 2022
2022-11-03 English
Active Biotech stärker ytterligare patentskyddet för laquinimod vid ögonsjukdomar med beviljat patent i USA
Regulatory Filings
2022-10-24 Swedish
Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US
Regulatory Filings
2022-10-24 English
Number of shares and votes in Active Biotech
Declaration of Voting Results & Voting Rights Announcements
2022-09-30 English
Antal aktier och röster i Active Biotech
Share Issue/Capital Change
2022-09-30 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-09-23 English
Active Biotech tillkännager slutligt utfall av bolagets företrädesemission
Share Issue/Capital Change
2022-09-07 Swedish
Active Biotech announces final outcome of the Company’s rights issue
Share Issue/Capital Change
2022-09-07 English
Active Biotech offentliggör prospekt
Report Publication Announcement
2022-08-16 Swedish
Active Biotech publishes prospectus
Report Publication Announcement
2022-08-16 English
Active Biotech announces a rights issue of approximately SEK 55 million
Share Issue/Capital Change
2022-08-04 English
Active Biotech offentliggör en nyemission om cirka 55 miljoner kronor
Share Issue/Capital Change
2022-08-04 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-08-04 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q2 2022
2022-08-04 English
Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
Regulatory Filings
2022-06-01 English
Det första steget av den kliniska fas IIa studien med naptumomab i kombination med docetaxel har framgångsrikt slutförts och rekryteringen till andra steget av studien pågår
Regulatory Filings
2022-06-01 Swedish
Årsstämma i Active Biotech AB
AGM Information
2022-05-19 Swedish
Annual General Meeting of Active Biotech AB
AGM Information
2022-05-19 English
FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
Regulatory Filings
2022-05-18 English
FDA beviljar särläkemedelsstatus för tasquinimod vid behandling av myelofibros
Regulatory Filings
2022-05-18 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF) FY 2021
2022-04-28 Swedish
Active Biotech strengthens the patent protection for laquinimod in eye disorders
Regulatory Filings
2022-04-26 English
Active Biotech stärker patentskyddet för laquinimod vid ögonsjukdomar
Regulatory Filings
2022-04-26 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-21 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-04-21 English
Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
AGM Information
2022-04-20 English
Active Biotech: KALLELSE TILL ÅRSSTÄMMA
AGM Information
2022-04-20 Swedish
Number of shares and votes in Active Biotech
Share Issue/Capital Change
2022-03-31 English
Antal aktier och röster i Active Biotech
Declaration of Voting Results & Voting Rights Announcements
2022-03-31 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-03-25 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q4 2021
2022-03-25 English
Regulatory Filings 2022
Regulatory Filings
2022-02-09 English
Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis
Regulatory Filings
2022-02-09 English
Active Biotech ingår globalt patentlicensavtal med Oncode Institute för tasquinimod i myelofibros
Regulatory Filings
2022-02-09 Swedish
Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma
Regulatory Filings
2022-02-07 English
Active Biotech meddelar att första patienten doserats i kombinationsdelen av fas Ib/IIa-studien av tasquinimod i multipelt myelom
Regulatory Filings
2022-02-07 Swedish
Active Biotech utser Erik Vahtola till Chief Medical Officer
Board/Management Information
2022-01-04 Swedish
Active Biotech Appoints Erik Vahtola as Chief Medical Officer
Board/Management Information
2022-01-04 English